Biomarker Testing for Actionable Alterations in NSCLC-Perspectives from US-Based Academic and Community Oncologists:...

Area of Science:

• Oncology
• Genomics
• Molecular Diagnostics

Background:

• Actionable oncogenic driver mutations in non-small cell lung cancer (NSCLC) guide therapy selection, improving clinical outcomes.
• Biomarker testing is recommended by guidelines but faces real-world unmet needs.
• A US perspective on challenges in biomarker testing for NSCLC is presented.

Purpose of the Study:

• To provide an overview of biomarker testing in NSCLC from academic and community oncologist viewpoints.
• To discuss the importance of comprehensive testing and actionable biomarkers.
• To identify and address challenges in real-world biomarker testing for NSCLC.

Main Methods:

• Discussion of guideline-recommended actionable biomarkers (NCCN, ESMO).
• Overview of test types and assessment techniques for actionable biomarkers.
• Analysis of challenges from academic and community oncologist perspectives.

Main Results:

• Key challenges identified: physician awareness, reimbursement inconsistencies, long turnaround times, and patient-related nihilism.
• Recommendations are offered to address these testing challenges.
• The importance of comprehensive biomarker testing for NSCLC is emphasized.

Conclusions:

• Addressing challenges in biomarker testing is essential for optimal NSCLC patient care.
• Improved awareness, streamlined processes, and consistent reimbursement can enhance biomarker testing.
• Collaborative efforts are needed to overcome barriers to effective NSCLC biomarker testing.